A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes

Lipids in Health and Disease

Volumn 16, Issue 1, 2017, Pages 1-8

  Cha, Seon Ah ^a   Park, Yong Moon ^b   Yun, Jae Seung ^a   Lim, Tae Seok ^a   Song, Ki Ho ^a   Yoo, Ki Dong ^c   Ahn, Yu Bae ^a   Ko, Seung Hyun ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c The Catholic University of Korea   (South Korea)

Author keywords

DPP 4 inhibitor; Lipid; SGLT2 inhibitor; Type 2 diabetes

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GEMIGLIPTIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LINAGLIPTIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; TRIACYLGLYCEROL; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; AGENTS AFFECTING WATER, MOLECULE OR ION TRANSPORT; BENZHYDRYL DERIVATIVE; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LC15-0444; PIPERIDONE DERIVATIVE; PYRIMIDINE DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG RESPONSE; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; LIPID ANALYSIS; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RETROSPECTIVE STUDY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VAGINA DISCHARGE; VAGINAL DISCOMFORT; ADVERSE EFFECTS; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; HYPERGLYCEMIA; HYPERLIPIDEMIAS; METABOLISM; RISK FACTOR; SOUTH KOREA;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC CARDIOMYOPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; LINAGLIPTIN; MALE; MEMBRANE TRANSPORT MODULATORS; MIDDLE AGED; PIPERIDONES; PYRIMIDINES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85018513669     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-017-0443-4     Document Type: Article

References (40)

1. Fox CS, Coady S, Sorlie PD, D'Agostino Sr RB, Pencina MJ, Vasan RS, et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham heart study. Circulation. 2007;115:1544-50.
2. Korean Diabetes Association. Korean Diabetes Fact Sheet. 2015. http://www.diabetes.or.kr/pro. Accessed 1 Feb 2016.
3. Franco OH, Steyerberg EW, Hu FB, Mackenbach J, Nusselder W. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. Arch Intern Med. 2007;167:1145-51.
4. American Diabetes Association. Cardiovascular disease and risk management. Diabetes Care. 2015;38(Suppl):S49-57.
5. Tancredi M, Rosengren A, Svensson AM, Kosiborod M, Pivodic A, Gudbjornsdottir S, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015;373:1720-32.
6. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care. 2002;25:482-6.
7. Tilly-Kiesi M, Syvanne M, Kuusi T, Lahdenpera S, Taskinen MR. Abnormalities of low density lipoproteins in normolipidemic type II diabetic and nondiabetic patients with coronary artery disease. J Lipid Res. 1992;33:333-42.
8. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5:150-9.
9. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American diabetes association and the American college of cardiology foundation. J Am Coll Cardiol. 2008;51:1512-24.
10. American Diabetes Association. Standards of Medical Care in Diabetes-2015. 2015. http://care.diabetesjournals.org/content/suppl/2014/12/23/38.Supplement_1.DC1/January_Supplement_Combined_Final.6-99.pdf. Accessed 5 Sep 2016.
11. Kirk JK, Huber KR, Clinch CR. Attainment of goals from national guidelines among persons with type 2 diabetes: a cohort study in an academic family medicine setting. N C Med J. 2005;66:415-9.
12. Fox CS, Golden SH, Anderson C, Bray GA, Burke LE, de Boer IH, et al. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence. A scientific statement from the American heart association and the American diabetes association. Circulation. 2015;132:691-718.
13. Jung JH, Lee JH, Noh JW, Park JE, Kim HS, Yoo JW, et al. Current status of management in type 2 diabetes mellitus at general hospitals in south Korea. Diabetes Metab J. 2015;39:307-15.
14. Ko SH, Kim DJ, Park JH, Park CY, Jung CH, Kwon HS, et al. Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002-2013: Nationwide population-based cohort study. Medicine (Baltimore). 2016;95:e4018.
15. Monami M, Lamanna C, Desideri CM, Mannucci E. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther. 2012;29:14-25.
16. Jung CH, Jang JE, Park JY. A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor. Diabetes Metab J. 2014;38:261-73.
17. Liu J, Sempos C, Donahue RP, Dorn J, Trevisan M, Grundy SM. Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. Diabetes Care. 2005;28:1916-21.
18. Rodriguez-Gutierrez R, Gonzalez-Saldivar G. Canagliflozin. Cleve Clin J Med. 2014;81:87-8.
19. Ko SH, Song KH, Ahn YB, Yoo SJ, Son HS, Yoon KH, et al. The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. Metabolism. 2003;52:731-4.
20. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461-70.
21. American Diabetes Association and National Kidney Foundation. Consensus development conference on the diagnosis and management of nephropathy in patients with diabetes mellitus. Diabetes Care 1994;17:1357-61.
22. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sci U S A. 1999;96:11041-8.
23. DeFronzo RA, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. Diabetes Care. 2008;31:2315-7.
24. Rhee EJ, Lee WY, Yoon KH, Yoo SJ, Lee IK, Baik SH, et al. A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metab. 2010;2:1113-9.
25. Ahren B, Schweizer A, Dejager S, Villhauer EB, Dunning BE, Foley JE. Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humans. Diabetes Obes Metab. 2011;13:775-83.
26. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med. 2011;28:1352-61.
27. Berhan A, Berhan Y. Efficacy of alogliptin in type 2 diabetes treatment: a meta-analysis of randomized double-blind controlled studies. BMC Endocr Disord. 2013;13:9.
28. Matikainen N, Taskinen MR. The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with type 2 diabetes. Diabet Med. 2013;30:756-7.
29. Ptaszynska A, Hardy E, Johnsson E, Parikh S, List J. Effects of dapagliflozin on cardiovascular risk factors. Postgrad Med. 2013;125:181-9.
30. US Food and Drug Administration. FDA Briefing Document NDA 204042 Invokana (canagliflozin) Tablets. 2013. http://www.fda.gov/downloads/AdvisoryCommittees/Committees Meeting Materials/Drugs/EndocrinologicandMetabolicDrugsAdvisory Committee/UCM334550.pdf. Accessed 1 Sep 2016.
31. Yang SJ, Min KW, Gupta SK, Park JY, Shivane VK, Pitale SU, et al. A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:410-6.
32. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-80.
33. Singh AB, Kan CF, Shende V, Dong B, Liu J. A novel posttranscriptional mechanism for dietary cholesterol-mediated suppression of liver LDL receptor expression. J Lipid Res. 2014;55:1397-407.
34. Briand F, Mayoux E, Brousseau E, Burr N, Urbain I, Costard C, et al. Empagliflozin, via switching metabolism toward lipid utilization, moderately increases LDL cholesterol levels through reduced LDL catabolism. Diabetes. 2016;65:2032-8.
35. Terawaki Y, Nomiyama T, Takahashi H, Tsutsumi Y, Murase K, Nagaishi R, et al. Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis. Diabetol Metab Syndr. 2015;7:44.
36. Foley JE, Jordan J. Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience. Vasc Health Risk Manag. 2010;6:541-8.
37. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Wu Y, et al. One-year treatment with exenatide vs. insulin glargine: effects on postprandial glycemia, lipid profiles, and oxidative stress. Atherosclerosis. 2010;212:223-9.
38. U.S. Food and Drug Administration. Highlights of prescribing information: Forxiga (dapagliflozin). http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/202293s003lbl.pdf. Accessed 28 August 2016.
39. Ogita M, Miyauchi K, Miyazaki T, Naito R, Konishi H, Tsuboi S, et al. Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol. Heart Vessels. 2014;29:35-41.
40. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374:1093-4.